Furthermore, SM-3 treatment led to a significant reduction in the levels of stem cell markers CD133 and CD44, as well as the stem cell transcription factors OCT4 and SOX2, compared to the spheroids treated with Res (50 μM) in lung cancer cells (Fig. 9D, S3D, S4D). This evidence concerns the gene SOX2 and lung carcinoma.